Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04548817 · ClinicalTrials.gov registry record
Neurocutaneous Melanocytosis Registry
A clinical trial of Cutaneous Melanocytic Neoplasm and Large Cutaneous Melanocytic Nevi, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT04548817: Recruiting study of Cutaneous Melanocytic Neoplasm and Large Cutaneous Melanocytic Nevi, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04548817 is a study of Cutaneous Melanocytic Neoplasm and Large Cutaneous Melanocytic Nevi that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 100 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04548817, a study of Cutaneous Melanocytic Neoplasm and Large Cutaneous Melanocytic Nevi, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).
Conditions Studied
Study Locations (2)
Massachusetts
- Boston Children's Hospital (Data Analysis Only) - Boston
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-09-03 |
| Est. Completion | 2027-09-03 |
What NCT04548817 shows while recruiting
NCT04548817 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 3 conditions, with Cutaneous Melanocytic Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT04548817 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04548817 about?
NCT04548817 is a clinical study titled "Neurocutaneous Melanocytosis Registry". This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).
What is the current status of trial NCT04548817?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2020-09-03. Estimated completion is 2027-09-03.
What conditions does trial NCT04548817 study?
This clinical trial studies the following conditions: Cutaneous Melanocytic Neoplasm, Large Cutaneous Melanocytic Nevi, Neurocutaneous Melanocytosis.
Who is sponsoring clinical trial NCT04548817?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04548817 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI